Valliant laboratories IPO Review

Valiant Laboratories, which mainly makes paracetamol and other drugs, saw its sales go up over time, but its profits were up and down. The money it made after all expenses (PAT) and its profit margins (RoCE) were going down too. Looking at how much it made in the financial year 2023, the IPO seems to be priced just right. People who know about investing might want to put their money in for the long run. In the year ending March 31, 2023, Valiant Laboratories made Rs 29 crore in profit with Rs 338.77 crore in sales. However, during that same time, it only made Rs 27.5 crore in profit with Rs 293.47 crore in sales.